Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationMultiple MyelomaMelphalanTransplantation, HomologousTransplantation ConditioningCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsRemission InductionTreatment OutcomeStem CellsSalvage TherapyDisease-Free SurvivalHodgkin DiseaseMyeloablative AgonistsEtoposideLymphoma, Non-HodgkinRecurrenceHematopoietic Stem Cell MobilizationCytarabineCyclophosphamideGraft vs Host DiseaseCarmustineBone Marrow TransplantationVincristineBone Marrow PurgingThiotepaSurvival RateHematologic NeoplasmsWhole-Body IrradiationLymphoma, Mantle-CellHematopoietic Stem CellsAmyloidosisRetrospective StudiesSurvival AnalysisBusulfanBoronic AcidsGraft SurvivalDexamethasonePyrazinesAntigens, CD34Lymphoma, T-Cell, PeripheralAntibodies, Monoclonal, Murine-DerivedLymphoma, FollicularPrognosisAutograftsLiver TransplantationDoxorubicinFollow-Up StudiesAntineoplastic Agents, AlkylatingThalidomideLeukapheresisMesenchymal Stem Cell TransplantationGranulocyte Colony-Stimulating FactorTime FactorsPrednisoneIfosfamideLymphomaPodophyllotoxinTransplantation ChimeraInduction ChemotherapyNeoplasm, ResidualTissue DonorsLymphoma, Large B-Cell, DiffuseCord Blood Stem Cell TransplantationMaintenance ChemotherapyCell TransplantationLeukemia, Myeloid, AcuteKidney TransplantationAntineoplastic AgentsEmbryonic Stem CellsEnteropathy-Associated T-Cell LymphomaMyelodysplastic SyndromesLymphoma, B-CellLeukemia, Plasma CellBlood Component RemovalInfusions, SpinalIdarubicinImmunosuppressive AgentsAdult Stem CellsMitoxantroneT-LymphocytesNeoplasms, Second PrimaryHistocompatibility TestingAntibodies, MonoclonalCell DifferentiationProspective StudiesBone MarrowHematopoiesisLeukemia, MyeloidCells, CulturedFeasibility StudiesHistocompatibilityKeratins, Type IIMesenchymal Stromal CellsFatal OutcomeFlow CytometryLeukocytes, Mononuclear